Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Mar 2

PMID 23451157

Citations 51

Authors

Rebeka Sultana

Tarek Abdel-Fatah

Christina Perry

Paul Moseley

Nada Albarakti

Vivek Mohan

Claire Seedhouse

Stephen Chan

Srinivasan Madhusudan

Affiliations

Soon will be listed here.

Abstract

Introduction: Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is a key sensor of single-stranded DNA associated with stalled replication forks and repair intermediates generated during DNA repair. XRCC1 is a critical enzyme in single strand break repair and base excision repair. XRCC1-LIG3 complex is also an important contributor to the ligation step of the nucleotide excision repair response.

Methods: In the current study, we investigated synthetic lethality in XRCC1 deficient and XRCC1 proficient Chinese Hamster ovary (CHO) and human ovarian cancer cells using ATR inhibitors (NU6027). In addition, we also investigated the ability of ATR inhibitors to potentiate cisplatin cytotoxicity in XRCC1 deficient and XRCC1 proficient CHO and human cancer cells. Clonogenic assays, alkaline COMET assays, γH2AX immunocytochemistry, FACS for cell cycle as well as FITC-annexin V flow cytometric analysis were performed.

Results: ATR inhibition is synthetically lethal in XRCC1 deficient cells as evidenced by increased cytotoxicity, accumulation of double strand DNA breaks, G2/M cell cycle arrest and increased apoptosis. Compared to cisplatin alone, combination of cisplatin and ATR inhibitor results in enhanced cytotoxicity in XRCC1 deficient cells compared to XRCC1 proficient cells.

Conclusions: Our data provides evidence that ATR inhibition is suitable for synthetic lethality application and cisplatin chemopotentiation in XRCC1 deficient ovarian cancer cells.

Citing Articles

Targeting ATR in patients with cancer.

Ngoi N, Pilie P, McGrail D, Zimmermann M, Schlacher K, Yap T Nat Rev Clin Oncol. 2024; 21(4):278-293.

PMID: 38378898 DOI: 10.1038/s41571-024-00863-5.

ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.

Lozinski M, Bowden N, Graves M, Fay M, Day B, Stringer B Oncotarget. 2024; 15:1-18.

PMID: 38227740 PMC: 10791076. DOI: 10.18632/oncotarget.28551.

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.

Dillon M, Guevara J, Mohammed K, Patin E, Smith S, Dean E J Clin Invest. 2023; 134(2).

PMID: 37934611 PMC: 10786692. DOI: 10.1172/JCI175369.

Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis.

Biswas H, Makinwa Y, Zou Y Int J Mol Sci. 2023; 24(14).

PMID: 37511442 PMC: 10380702. DOI: 10.3390/ijms241411684.

Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity.

Taghizadeh-Hesary F, Houshyari M, Farhadi M J Cancer Res Clin Oncol. 2023; 149(9):6719-6741.

PMID: 36719474 DOI: 10.1007/s00432-023-04592-7.

References

Caldecott K . XRCC1 and DNA strand break repair. DNA Repair (Amst). 2003; 2(9):955-69. DOI: 10.1016/s1568-7864(03)00118-6. View

Svilar D, Goellner E, Almeida K, Sobol R . Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal. 2010; 14(12):2491-507. PMC: 3096496. DOI: 10.1089/ars.2010.3466. View

Sultana R, McNeill D, Abbotts R, Mohammed M, Zdzienicka M, Qutob H . Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer. 2012; 131(10):2433-44. PMC: 3742328. DOI: 10.1002/ijc.27512. View

Sirbu B, Lachmayer S, Wulfing V, Marten L, Clarkson K, Lee L . ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells. PLoS One. 2011; 6(8):e23053. PMC: 3155521. DOI: 10.1371/journal.pone.0023053. View

Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F . Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer. 2009; 65(2):230-6. DOI: 10.1016/j.lungcan.2008.11.014. View

Shuck S, Short E, Turchi J . Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res. 2008; 18(1):64-72. PMC: 2432112. DOI: 10.1038/cr.2008.2. View

Toledo L, Murga M, Fernandez-Capetillo O . Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol. 2011; 5(4):368-73. PMC: 3590794. DOI: 10.1016/j.molonc.2011.07.002. View

Ladiges W . Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006; 25(11):1612-9. DOI: 10.1038/sj.onc.1209370. View

Zhang R, Niu Y, Zhou Y . Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett. 2009; 192(2):108-14. DOI: 10.1016/j.toxlet.2009.10.012. View

10.

Fan J, Wilson P, Wong H, Urbin S, Thompson L, Wilson 3rd D . XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. Environ Mol Mutagen. 2007; 48(6):491-500. DOI: 10.1002/em.20312. View

11.

Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S . Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. Int J Cancer. 2012; 132(12):2778-86. DOI: 10.1002/ijc.27980. View

12.

Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain J . XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004; 22(13):2594-601. DOI: 10.1200/JCO.2004.08.067. View

13.

Cliby W, Lewis K, Lilly K, Kaufmann S . S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem. 2001; 277(2):1599-606. DOI: 10.1074/jbc.M106287200. View

14.

Caldecott K, Tucker J, Thompson L . Construction of human XRCC1 minigenes that fully correct the CHO DNA repair mutant EM9. Nucleic Acids Res. 1992; 20(17):4575-9. PMC: 334187. DOI: 10.1093/nar/20.17.4575. View

15.

Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G . PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301. PMC: 2910902. DOI: 10.1038/nrc2812. View

16.

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

17.

Cimprich K, Cortez D . ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008; 9(8):616-27. PMC: 2663384. DOI: 10.1038/nrm2450. View

18.

BERENBAUM M . Criteria for analyzing interactions between biologically active agents. Adv Cancer Res. 1981; 35:269-335. DOI: 10.1016/s0065-230x(08)60912-4. View

19.

Peasland A, Wang L, Rowling E, Kyle S, Chen T, Hopkins A . Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer. 2011; 105(3):372-81. PMC: 3172902. DOI: 10.1038/bjc.2011.243. View

20.

Nam E, Cortez D . ATR signalling: more than meeting at the fork. Biochem J. 2011; 436(3):527-36. PMC: 3678388. DOI: 10.1042/BJ20102162. View